Literature DB >> 2272024

Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys.

S Boyce1, N M Rupniak, M J Steventon, S D Iversen.   

Abstract

We examined the ability of L-DOPA to induce dyskinesias in MPTP-treated and normal squirrel monkeys to establish whether the underlying neuropathology associated with parkinsonism is an absolute requirement or merely promotes the development of drug-induced dyskinesias. Administration of L-DOPA (5-40 mg/kg p.o., following a 60 min pretreatment with carbidopa 2.5-20 mg/kg p.o.) induced a range of dopamine-mediated behaviours including locomotor activity, stereotyped scratching, and climbing in both lesioned and nonlesioned animals. However, the dose-response curves showed a marked (three- to fourfold) shift to the left in lesioned animals, indicating behavioural supersensitivity. In contrast, L-DOPA-induced dyskinesias were only observed in MPTP-treated monkeys. Doses required for induction of dyskinesias were lower than those required to induce climbing. These findings provide further evidence that nigrostriatal damage is essential for the genesis of L-DOPA-induced dyskinesias.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2272024     DOI: 10.1097/00002826-199010000-00006

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  19 in total

1.  The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model.

Authors:  Sukju Gil; Changhwan Park; Jeongeun Lee; Hyunchul Koh
Journal:  Cell Mol Neurobiol       Date:  2010-03-16       Impact factor: 5.046

2.  Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys.

Authors:  Christopher A Lieu; Milind Deogaonkar; Roy A E Bakay; Thyagarajan Subramanian
Journal:  Parkinsonism Relat Disord       Date:  2010-11-11       Impact factor: 4.891

Review 3.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

4.  Baseline cognitive profile is closely associated with long-term motor prognosis in newly diagnosed Parkinson's disease.

Authors:  Seok Jong Chung; Han Soo Yoo; Hye Sun Lee; Yang Hyun Lee; KyoungWon Baik; Jin Ho Jung; Byoung Seok Ye; Young H Sohn; Phil Hyu Lee
Journal:  J Neurol       Date:  2021-05-04       Impact factor: 4.849

Review 5.  Dyskinesias and levodopa therapy: why wait?

Authors:  Michele Matarazzo; Alexandra Perez-Soriano; A Jon Stoessl
Journal:  J Neural Transm (Vienna)       Date:  2018-02-10       Impact factor: 3.575

Review 6.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

Review 7.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

Review 8.  Long term motor complications of levodopa: clinical features, mechanisms, and management strategies.

Authors:  B R Thanvi; T C N Lo
Journal:  Postgrad Med J       Date:  2004-08       Impact factor: 2.401

Review 9.  Levodopa-induced dyskinesias and their management.

Authors:  Francesca Del Sorbo; Alberto Albanese
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

10.  Long term treatment and disease severity change brain responses to levodopa in Parkinson's disease.

Authors:  T Hershey; K J Black; J L Carl; L McGee-Minnich; A Z Snyder; J S Perlmutter
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-07       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.